Obstet Gynecol Sci.  2020 Jul;63(4):470-479. 10.5468/ogs.20012.

Effect of gynecological cancer and its treatment on bone mineral density and the risk of osteoporosis and osteoporotic fracture

• Lee JE
• Park CY
• Lee E
• Ji YI

• KMID: 2505037
• DOI: http://doi.org/10.5468/ogs.20012

Abstract

Objective
The purpose of this study was to evaluate the risk of osteopenia and osteoporosis by examining the bone mineral density (BMD) of the lumbar spine and femur in patients with gynecological cancer without bone metastasis and to evaluate the impact of treatment for different cancers on BMD.
Methods
This study retrospectively reviewed the medical records of 243 women with gynecological cancer and 240 controls between March 2010 and December 2016. Patients with cervical cancer (n=105), endometrial cancer (n=63), and ovarian cancer (n=75) were treated with total hysterectomy including bilateral salpingo-oophorectomy and/or chemotherapy and/or radiotherapy. For the control group, healthy post-menopausal women without gynecologic cancer were selected.
Results
Before anticancer treatment, the BMD of patients with cervical cancer and ovarian cancer was significantly lower than that of the controls, and the BMD of patients with endometrial cancer was not significantly different from that of the controls. However, the BMD of endometrial cancer significantly decreased after treatment. According to the treatment methods, there were significant differences in the BMD of L3, L4, and the femur neck. Changes in the BMD were lowest in patients who underwent surgical treatment only, and the highest bone loss was found in patients who underwent postoperative concurrent chemoradiotherapy.
Conclusion
Patients with cervical and ovarian cancer had lower BMD than those in the control group before treatment, and patients with endometrial cancer had decreased bone density after treatment. Therefore, during the treatment of gynecological cancer, strategies should be implemented to mitigate these risks.

Keyword

Bone density; Treatment-associated cancer; Osteoporosis

Figure

• 

  Fig. 1. The T-scores of the lumbar spine and femur neck in patients with gynecologic cancer before and after treatment. BMD, bone mineral density.

Reference

References

1. Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res. 2000; 15:710–20.

2. Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause. 2007; 14:567–71.

3. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 1994; 35:2083–93.

4. Nguyen TV, Jones G, Sambrook PN, White CP, Kelly PJ, Eisman JA. Effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures. J Clin Endocrinol Metab. 1995; 80:2709–14.

5. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163:181–6.

6. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002; 167:2361–7.

7. Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999; 54:607–11.

8. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 1996; 276:1404–8.

9. Atkins CD. Bone mass and the risk of breast cancer. N Engl J Med. 1997; 337:199–200.

10. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997; 336:611–7.

11. Mundy G, Eilon G, Orr W, Spiro T, Yoneda T. Osteoclast activating factor: its role in myeloma and other types of hypercalcaemia of malignancy. Metab Bone Dis Relat Res. 1980; 2:173–6.

12. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm. 2006; 63:419–30.

13. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000; 18:1570–93.

14. Bonfiglio M. The pathology of fracture of the femoral neck following irradiation. Am J Roentgenol Radium Ther Nucl Med. 1953; 70:449–59.

15. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9:1137–41.

16. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002; 359:1929–36.

17. Seyberth HW, Segre GV, Morgan JL, Sweetman BJ, Potts JT Jr, Oates JA. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975; 293:1278–83.

18. Martin T, Partridge N. Prostaglandins, cancer and bone: pharmacological considerations. Metab Bone Dis Relat Res. 1980; 2:167–71.

19. Sherwin SA, Twardzik DR, Bohn WH, Cockley KD, Todaro GJ. High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res. 1983; 43:403–7.

20. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 1987; 237:893–6.

21. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, et al. Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest. 1987; 80:1803–7.

22. Lee Y, Kim A, Kim HY, Eo WK, Lee ES, Chun S. Bone density in patients with cervical cancer or endometrial cancer in comparison with healthy control; according to the stages. J Cancer. 2015; 6:686–93.

23. Cho SH, Cho SH, Lee JA, Moon H, Kim DS. Reduced spinal bone mass in patients with uterine cervical cancer. Obstet Gynecol. 1991; 78:689–92.

24. Hung YC, Yeh LS, Chang WC, Lin CC, Kao CH. Prospective study of decreased bone mineral density in patients with cervical cancer without bone metastases: a preliminary report. Jpn J Clin Oncol. 2002; 32:422–4.

25. Lee SW, Yeo SG, Oh IH, Yeo JH, Park DC. Bone mineral density in women treated for various types of gynecological cancer. Asia Pac J Clin Oncol. 2016; 12:e398–404.

26. Douchi T, Yamamoto S, Nakamura S, Oki T, Maruta K, Nagata Y. Bone mineral density in postmenopausal women with endometrial cancer. Maturitas. 1999; 31:165–70.

27. Möllerström G, Lagrelius A, Carlström K, Sjöberg HE. Denser trabecular bone in women with endometrial carcinoma. Int J Gynecol Cancer. 1994; 4:161–8.

28. Persson I, Naessén T, Adami HO, Bergström R, Lagrelius A, Möllerström G, et al. Reduced risk of hip fracture in women with endometrial cancer. Int J Epidemiol. 1992; 21:636–42.

29. Persson I, Adami HO, McLaughlin JK, Naessén T, Fraumeni JF Jr. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control. 1994; 5:523–8.

30. McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, et al. Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer. 2008; 122:1879–84.

31. Mundy GR, Ibbotson KJ, D’Souza SM, Simpson EL, Jacobs JW, Martin TJ. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med. 1984; 310:1718–27.

32. Hwang JH, Song SH, Lee JK, Lee NW, Lee KW. Bone mineral density after concurrent chemoradiation in patients with uterine cervical cancer. Menopause. 2010; 17:416–20.

33. Nishio K, Tanabe A, Maruoka R, Nakamura K, Takai M, Sekijima T, et al. Bone mineral loss induced by anticancer treatment for gynecological malignancies in premenopausal women. Endocr Connect. 2012; 2:11–7.

34. Lee SH, Ku CH, Shin JW, Park JM, Park CY. Bone mineral density in patients with endometrial cancer. J Korean Soc Menopause. 2009; 15:35–40.

35. Chen HH, Lee BF, Guo HR, Su WR, Chiu NT. Changes in bone mineral density of lumbar spine after pelvic radiotherapy. Radiother Oncol. 2002; 62:239–42.

36. Oh D, Huh SJ, Nam H, Park W, Han Y, Lim DH, et al. Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors. Int J Radiat Oncol Biol Phys. 2008; 70:1183–8.